Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2009 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (162)	2/6/2009 4:09:46 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 418

Thanks, Cary. There are tons of good companies that I won't consider. I don't consider rare disease models, as it's not what I pictured when molecular biology met business. I pictured inexpensive medicines, not pricing that holds Earth hostage. Nope, never held gtxi in real world or contest. Compelling reason to do so, and I will..... anybody got one? (that is, I barely know the sucker.... angling today, ya know?) I'll take a look at MITI. Best! Rick

To: Arthur Radley who wrote (162)	2/7/2009 2:14:07 AM
From: scaram(o)uche	Respond to of 418

Hey, there's a thread! Subject 56411 :-) OK, well...... way back in the early 90s, I coordinated a brief collaboration between XOMA and Biotherapeutics. Brief, as Biotherapeutics rapidly progressed to pushing up daisies. My primary contact at BT was the now CEO of SGMO, Ed Lamphier. We had this wonderful "activating" antibody from Sloan Kettering, which hits a unique epitope on a T cell molecule known as CD1. The concept was to complement this MAb with one of XOMA's putative anti-melanoma MAbs, constructing bispecific antibodies. BT actually was doing great work, handing us preps of truly bispecific molecules. Trouble was, little in the world of XOMA, at that time, was actually as advertised. Anyway..... very old concept (BiTE), would love to see it work. It works in controlled in vitro conditions, no sweat. But T cells are big giant things and antibodies are eeensy teensy. Antibodies can't steer cells around, so the cells just bump into the antibodies while stuck on solid tumors??? Why would they do that? Or antibody-coated cells just bump into cancer cells? How? In the earliest days of Medarex, they were using anti-Fc receptor MAbs mixed with cancer-targeted MAbs, very similar concept. Thanks again, let's hope it works. Rick edit: ah, I see from their press releases that they're starting with lymphomas and leukemias. good.